secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELI LILLY & Co (LLY)
CIK:        0000059478
Form:       8-K
Filed at:   2022-02-03T23:59:59+00:00
Accession:  0000059478-22-000016
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lilly Q4 2021 non-GAAP EPS $2.49 (+8%), revenue $8.0B +8%; 2022 guidance reaffirmed
--------------------------------------------------------------------------------

- Q4 revenue $7,999.9M (+8% YoY); non-GAAP EPS $2.49 (+8%).
- Full-year revenue $28,318.4M (+15%); non-GAAP EPS $8.16 (+20%).
- COVID-19 antibody revenue $1.06B in Q4, $2.24B for full year.
- Key growth products (Trulicity, Taltz, Verzenio, Jardiance, Olumiant) contributed 14 ppt revenue growth ex-COVID.
- 2022 EPS guidance: GAAP $8.00-$8.15, non-GAAP $8.50-$8.65; dividend raised 15%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/59478/000005947822000016/0000059478-22-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/59478/000005947822000016/lly-20220203.htm
  HTML page:      https://secwatch.observer/filing/0000059478-22-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer